Johannes F.E. Mann

Research interests

Publications

• Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

  New England Journal of Medicine · 2025 · https://doi.org/10.1056/nejmoa2501006

• Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

  New England Journal of Medicine · 2025 · 10.1056/nejmoa2410659

• Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2403347

• Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

  The Lancet Diabetes & Endocrinology · 2024 · https://doi.org/10.1016/s2213-8587(24)00271-7

• Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

  Kidney International · 2021 · https://doi.org/10.1016/j.kint.2020.10.026

• KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

  Kidney International · 2021 · https://doi.org/10.1016/j.kint.2020.11.003

• Dapagliflozin in Patients with Chronic Kidney Disease

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2024816

• Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

  Kidney International · 2019 · https://doi.org/10.1016/j.kint.2019.09.018

• Liraglutide and Renal Outcomes in Type 2 Diabetes

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1616011

• Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)30754-7

• Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)30467-6

• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1603827

• Intensive Supportive Care plus Immunosuppression in IgA Nephropathy

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1415463

• Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

  The Lancet · 2013 · https://doi.org/10.1016/s0140-6736(13)60595-4

• Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Events

  JAMA · 2011 · https://doi.org/10.1001/jama.2011.1729

• Avosentan for Overt Diabetic Nephropathy

  Journal of the American Society of Nephrology · 2010 · https://doi.org/10.1681/asn.2009060593

• Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease

  Annals of Internal Medicine · 2008 · https://doi.org/10.7326/0003-4819-148-1-200801010-00190

• Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

  The Lancet · 2008 · 10.1016/s0140-6736(08)61236-2

• Chronic Kidney Disease

  Circulation · 2007 · https://doi.org/10.1161/circulationaha.106.678342

• Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease

  American Heart Journal · 2005 · https://doi.org/10.1016/j.ahj.2004.07.009

• Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis

  New England Journal of Medicine · 2005 · 10.1056/nejmoa043545

• Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)

  BMJ · 2004 · 10.1136/bmj.37970.629537.0d

• Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes

  Diabetes Care · 2002 · https://doi.org/10.2337/diacare.25.11.1919

• Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial

  Annals of Internal Medicine · 2001 · https://doi.org/10.7326/0003-4819-134-8-200104170-00007

• Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

  New England Journal of Medicine · 1996 · https://doi.org/10.1056/nejm199604113341502

Current projects

No projects listed.